StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) income statement

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.56−0.05 (-7.95%)

Close on Nov 20, 2026Market cap $21.34MP/E –Yield –

Metagenomi Therapeutics, Inc. financial ratios

See a number that looks wrong?